Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss

NCT07280403 · Completed

Last updated 2026-05-28

This clinical trial tests whether a low-carbohydrate diet affects weight loss in adults who are using the injectable medication semaglutide for weight management.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2024-09 · est. completion 2025-11

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07280403 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to determine the effect of a low carbohydrate higher protein diet, modelled after the Atkins program on weight loss, glycemic control, risk markers of cardiovascular disease and body composition in patients taking semaglutide. Participants will: * Be randomized to follow either a low carb, higher protein diet or a low fat diet for 3 months. * Visit the clinic at week 2, 4, 8 and 12 to meet with a dietician, fill out a symptoms questionnaire and for bloodwork * Complete 3-day food records 4 times over the 12 weeks.

Treatments tested

Low Carbohydrate Behavioral

Low carbohydrate diet
Low Fat Behavioral

Low fat diet

Main thing measured	Body weight
Sponsor	INQUIS Clinical Research
Conditions studied	Weight Loss
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07280403 ↗